The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.